Ignite Creation Date:
2025-12-25 @ 2:05 AM
Ignite Modification Date:
2025-12-26 @ 5:03 PM
Study NCT ID:
NCT05604560
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-07-23
First Post:
2022-10-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Sponsor:
Lei Zheng
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Pancreatic Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Pancreatic cancer | View |
| None | Adenocarcinoma | View |
| None | Resectable pancreas cancer | View |
| None | Tislelizumab | View |
| None | Anti-PD-1 | View |
| None | PD-L1 | View |
| None | Antibody | View |
| None | SX-682 | View |
| None | CXCR1/2 (chemokine receptor) | View |
| None | CXCR1/2 inhibitor | View |
| None | Small molecule | View |
| None | Immunotherapy | View |